FDA approves AbbVie’s Mavyret for children with Hepatitis C (HCV)
May 1, 2019Research and Development AbbVie, HCV, hepatitis C, mavyret, pharma
The FDA has approved AbbVie’s Mavyret tables (glecaprevir/pibrentasvir) as a treatment for hepatitis C (HCV) in children aged 12 to 17 …
FDA refuses to review Nabriva’s injectable antibiotic for urinary tract infections
May 1, 2019Research and Development, Sales and Marketing Contepo, Nabriva, pharma, urinary tract infections
Biopharma firm Nabriva Therapeutics has revealed that its antibiotic Contepo (fosfomycin) has been rejected for review by the FDA as …
Diabetes drug may help people quit smoking
May 1, 2019Research and Development UTHealth, clinical trials, diabetes, smoking smoking cessation
A diabetes drug may help people quit smoking, according to researchers at the University of Texas Health Science Center at …
Gilead’s CFO and Executive Vice President to depart in 2020
May 1, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, appointment, pharma
Gilead has announced that Robin Washington, the company’s Senior Vice President and Chief Financial Officer of more than a decade, …
Scientists identify new form of dementia
May 1, 2019Research and Development AD, Alzheimer's, dementia, late, neuroscience
A team of scientists from Britain and the United States have described a new form of dementia, according to a …
GSK’s Benlysta becomes first FDA-approved IV therapy for paediatric lupus
April 30, 2019Manufacturing and Production, Sales and Marketing Benlysta, FDA, GSK, Lupus, US, pharma
GSK has scored approval in the US with Benlysta (belimumab) for the treatment of systemic lupus erythematosus (SLE) in paediatric …
Two thirds of MPs believe NHS should spend less on medicines
April 30, 2019Manufacturing and Production Long Term Plan, MPs, NHS, UK, government, health, public health
Nearly two thirds (64%) of MPs believe the NHS should direct more resources towards prevention, over funding for new treatments, …
Donald Trump says he will not accept campaign money from pharma
April 30, 2019Manufacturing and Production Donald Trump, USA, campaign contributionss, pharma, politics
President Donald Trump has said he will not accept money from pharmaceutical companies in the run up to the 2020 …
New Phase 3 data confirms safety and efficacy of UCB’s Cimzia in plaque and psoriatic arthritis
April 30, 2019Manufacturing and Production, Research and Development Cimzia, UCB Pharma, pharma, plaque psoriasis, psoriasis
New Phase 3 data has been released by UCB Pharma on the safety of Cimzia (certolizumab pegol) in the treatment …
Stanford scientists develop test for ME
April 30, 2019Manufacturing and Production CFS, ME, diagnosis, electric curernt, immune system, nanoelectronic assay
Scientists from Stanford University have, for the first time, developed a test for Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The blood …
The price of access: Can the NHS afford Orkambi?
April 29, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug pricing, NHS, NICE, Orkambi, UK, Vertex, access, cystic fibrosis, feature, pharma, pricing
The impasse over access to Vertex’s Orkambi for cystic fibrosis patients in England and Wales has revealed the cracks in …
Sanofi and Lexicon’s Zynquista scores EU approval for type 1 diabetes patients
April 29, 2019Sales and Marketing Lexicon, Sanofi, Type 1 diabetes, Zynquista, diabetes, pharma
The European Commission has authorised the use of Sanofi and Lexicon’s Zynquista (sotagliflozin) in Europe in the treatment of specific …
Gilead subsidiary Kite Pharma to open CAR-T manufacturing facility in Maryland
April 29, 2019Manufacturing and Production, Sales and Marketing CAR-T, Gilead, Manufacturing Facility, Maryland, kite pharma
Gilead Sciences subsidiary Kite Pharma has announced plans to open a new CAR-T manufacturing facility in Frederick County, Maryland (US). …
AZ and MSD’s Lynparza secures CHMP nod in first-line BRCA-mutated ovarian cancer
April 29, 2019Sales and Marketing AstraZeneca, CHMP, Cancer, MSD, lynparza, ovarian cancer, pharma
AstraZeneca and MSD’s Lynparza (olaparib) has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use …
India hits back at claims they are leading source of counterfeit drugs
April 29, 2019Sales and Marketing
India has rejected claims that they, along with China, are the chief source of counterfeit medicines around the world. In …
Opioids to be labelled with addiction warning in UK
April 29, 2019Sales and Marketing
All opioid medicines sold in the UK will be labelled with a warning as to the potential for addiction, Health …
Gilead’s selonsertib crashes at Phase 3 in NASH
April 26, 2019Medical Communications, Research and Development, Sales and Marketing Gilead, nash, pharma, selonsertib
Gilead has broken the news that its apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib failed to meet its primary endpoint …
Top Ten most popular articles on Pharmafile.com this week!
April 26, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Aduro Biotech, Cancer, GSK, ICR, J&J, JJ, Novartis, Sandoz, pharma
The Institute for Cancer Research (ICR) called for new measures to increase the speed with which patients in the UK …
Senior GSK exec Richard Saynor revealed as new Sandoz CEO
April 26, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Novartis has seen a major leadership change within its business, as the company announced that senior GlaxoSmithKline exec Richard Saynor …
Eli Lilly to withdraw Lartruvo from market in soft tissue sarcoma following Phase 3 failure
April 26, 2019Medical Communications, Sales and Marketing Cancer, Eli Lilly, Lartruvo, pharma, soft tissue sarcoma
Eli Lilly has revealed it is to withdraw its platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody Lartruvo (olaratumab) from …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
